Sanara Medtech INC 8-K filings

Sanara MedTech Inc. has entered into a separation agreement with its former CEO, Zachary B. Fleming, outlining the terms of his departure and associated benefits.

Sanara MedTech reported its tenth consecutive record revenue quarter, a CEO resignation, and secured a $55 million term loan.

Sanara MedTech has secured a $55 million term loan to support growth initiatives, including potential acquisitions and working capital.

Sanara MedTech Inc. has announced the appointment of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer, effective April 15, 2024 and April 1, 2024 respectively.

Sanara MedTech achieved record revenue of $17.7 million in the fourth quarter of 2023 and a 42% increase in full-year revenue, alongside significant improvements in profitability.

Sanara MedTech Inc.'s Board of Directors has adopted amended and restated bylaws, effective immediately, to modernize governance practices and update shareholder meeting procedures.

Sanara MedTech reported a 41.8% increase in full-year revenue for 2023, driven by strong sales of soft tissue repair and bone fusion products.